Improvement In Overall Survival (OS) And Tolerability Seen In Patients Receiving Trilaciclib With A TROP2 Antibody-Drug Conjugate (ADC)
Portfolio Pulse from Benzinga Newsdesk
G1 Therapeutics, Inc. (NASDAQ:GTHX) announced positive Phase 2 clinical trial results showing improved overall survival (OS) and tolerability for patients receiving trilaciclib in combination with a TROP2 ADC (sacituzumab govitecan) compared to historical data from the ASCENT trial.
May 28, 2024 | 10:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
G1 Therapeutics, Inc. (NASDAQ:GTHX) announced positive Phase 2 clinical trial results showing improved overall survival (OS) and tolerability for patients receiving trilaciclib in combination with a TROP2 ADC (sacituzumab govitecan) compared to historical data from the ASCENT trial.
The positive Phase 2 trial results are likely to boost investor confidence in G1 Therapeutics' product pipeline, potentially leading to a short-term increase in stock price. Improved overall survival and tolerability are significant factors in oncology treatments, making this news highly relevant and important for the company.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100